Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

medic d.o.o., zagreb - kanulacija duktalnog sistema i sfinkterotomija

Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

medic d.o.o., zagreb - drenaža cerebrospinalne tekućine

Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

johnson & johnson s.e. d.o.o., zagreb - kateter za ubrizgavanje agensa u miokard

Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

sonimed d.o.o., zagreb - kateter putem kojeg se mjeri vrijednost rada srca u smislu snage izbačaja i volumena izbačene krvi

Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

dispomed promet d.o.o., zagreb - kateter za intraaortalnu balon pumpu kao mehanička pomoć rada lijeve srčane klijetke

Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

mark medical d.o.o., zagreb - sistemi za davanje infuzije različitih terapijskih otopina u perifernu vaskulaturu bolesnika

Europska Unija - hrvatski - EMA (European Medicines Agency)

janssen-cilag international n.v. - daratumumab - multipli mijelom - monoclonal antibodies and antibody drug conjugates, antineoplastic agents - multiple myelomadarzalex is indicated: in combination with lenalidomide and dexamethasone or with bortezomib, melphalan and prednisone for the treatment of adult patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant. u kombinaciji s бортезомибом, талидомидом i дексаметазоном za liječenje odraslih bolesnika s prvi put utvrđenom multiplog mijeloma, koji imaju pravo za obavljanje autologna transplantacija matičnih stanica . u kombinaciji s леналидомидом i дексаметазоном i бортезомибом i дексаметазоном za liječenje odraslih bolesnika s multiplog mijeloma, koji je dobio barem jedne prethodne terapije. in combination with pomalidomide and dexamethasone for the treatment of adult patients with multiple myeloma who have received one prior therapy containing a proteasome inhibitor and lenalidomide and were lenalidomide refractory, or who have received at least two prior therapies that included lenalidomide and a proteasome inhibitor and have demonstrated disease progression on or after the last therapy (see section 5. u monoterapiji za liječenje odraslih bolesnika s ponavljajućom i uporan multiplog mijeloma, čija je ranije terapija je uključivala inhibitor протеасом i иммуномодулирующего agent i koji je pokazao napredovanje bolesti na zadnje terapije. al amyloidosisdarzalex is indicated in combination with cyclophosphamide, bortezomib and dexamethasone for the treatment of adult patients with newly diagnosed systemic light chain (al) amyloidosis.

Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

medical intertrade d.o.o., sveta nedelja - trans-kateterski okluderi za zatvaranje različitih oštećenja na srcu

Europska Unija - hrvatski - EMA (European Medicines Agency)

amgen europe b.v. - blinatumomab - prekursorska stanica limfoblastične leukemije-limfom - antineoplastična sredstva - blincyto is indicated as monotherapy for the treatment of adults with cd19 positive relapsed or refractory b precursor acute lymphoblastic leukaemia (all). patients with philadelphia chromosome positive b-precursor all should have failed treatment with at least 2 tyrosine kinase inhibitors (tkis) and have no alternative treatment options. blincyto is indicated as monotherapy for the treatment of adults with philadelphia chromosome negative cd19 positive b-precursor all in first or second complete remission with minimal residual disease (mrd) greater than or equal to 0. blincyto is indicated as monotherapy for the treatment of paediatric patients aged 1 year or older with philadelphia chromosome negative cd19 positive b precursor all which is refractory or in relapse after receiving at least two prior therapies or in relapse after receiving prior allogeneic haematopoietic stem cell transplantation. blincyto is indicated as monotherapy for the treatment of paediatric patients aged 1 year or older with high-risk first relapsed philadelphia chromosome negative cd19 positive b-precursor all as part of the consolidation therapy (see section 4.

Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

tehmed d.o.o. pula - za sprečavanje zgrušavanja krvi u centralnom venskom kateteru i njegovo zatvaranje kada nije u uporabi